Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 13, 2026

Study Completion Date

December 31, 2026

Conditions
Crohn Disease (CD)
Interventions
DRUG

After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks

Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker).

Trial Locations (12)

75010

RECRUITING

CHU Saint Louis, Paris

75012

RECRUITING

Hôpital Saint Antoine, Paris

94270

RECRUITING

Hôpital Bicêtre, Le Kremlin-Bicêtre

Unknown

RECRUITING

CHU Clermont-Ferrand, Clermont-Ferrand

RECRUITING

Hôpital Henri Mondor, Créteil

RECRUITING

CHU Lille, Lille

RECRUITING

Hospices civils Lyon Sud, Lyon

RECRUITING

CHU Marseille Nord, Marseille

RECRUITING

CHU Montpellier, Montpellier

RECRUITING

CHU Nancy, Nancy

RECRUITING

CHU Nantes, Nantes

RECRUITING

CHU Nice Archet 2, Nice

All Listed Sponsors
lead

Madeleine Bezault

OTHER